Modulating mitochondrial dynamics in CMT2A: a multifaceted platform for drug discovery and evaluation

Area of Science:

• Cell Biology
• Neuroscience
• Drug Discovery

Background:

• Mitochondrial dynamics (fusion/fission) are vital for cellular functions, especially in the nervous system.
• Mitofusin-2 (MFN2) mutations cause Charcot-Marie-Tooth disease type 2A (CMT2A), a peripheral neuropathy with no cure.
• Previous work identified S89, a small molecule that promotes mitochondrial fusion and reduces axonal degeneration in CMT2A models.

Purpose of the Study:

• To develop and validate a comprehensive drug-screening platform for identifying CMT2A therapeutics.
• To leverage S89 as a benchmark compound within the screening platform.

Main Methods:

• A three-stage screening platform was established: initial screening in Mfn knockout mouse embryonic fibroblasts (MEFs), followed by evaluation in CMT2A mouse primary neuronal cultures, and finally, assessment in patient-derived induced pluripotent stem cell (iPSC)-differentiated motor neurons.
• The platform assesses mitochondrial fragmentation, morphology, axonal transport, and neurite outgrowth.

Main Results:

• The developed platform enables rapid screening of compounds with increasing physiological relevance.
• The platform is designed to enhance the efficiency and translational potential of identifying CMT2A therapeutic candidates.
• S89 demonstrated efficacy in mitigating axonal degeneration in CMT2A models.

Conclusions:

• The multi-tiered drug-screening platform is effective for identifying potential therapeutics for CMT2A.
• This approach accelerates the discovery of treatments for peripheral neuropathies linked to mitochondrial dysfunction.
• The platform holds promise for advancing therapeutic strategies for CMT2A and similar neurodegenerative diseases.